Morepen Laboratories Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹746 Cr +81.1% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
ML

Morepen Laboratories Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Morepen Laboratories Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹412Cr
−5.9% YoY
−3.1% QoQ
Net profit
₹41Cr
+17.1% YoY
+272.7% QoQ
Margin
7%
−3 pp YoY
+1 pp QoQ

Based on Morepen Laboratories Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹117
Market cap₹6.6K Cr
P/E56.4

The short version

Pharma Business (Total Revenue): EBITDA:

From Morepen Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Pharma Business (Total Revenue):
  • Q2 FY26: Rs. 248 Crores
  • Q2 FY25: Rs. 235 Crores
  • YoY Growth: ~5.5%
  • Pharma Business (Standalone Revenue):
  • Q2 FY26: Rs. 374 Crores
  • Q2 FY25: Rs. 395 Crores
  • YoY Change: Slight decline (~5.3%)
  • API Revenue:
  • H1 FY26: Rs. 424 Crores
  • H1 FY25: Rs. 455 Crores
  • YoY Change: Decline (~6.8%)
  • Medical Devices Revenue:
  • Q2 FY26: Rs. 126 Crores
  • Q2 FY25: Rs. 133 Crores
  • YoY Change: Decline (~5.3%)
  • Glucometer Sales:
  • Q2 FY26 Revenue: Rs. 97 Crores (down from Rs. 103 Crores in Q2 FY25)
  • Operating Profit (EBITDA):
  • Consolidated Q2 FY26: Rs. 35 Crores (up from Rs. 29 Crores in Q1 FY26)

2 more points from Morepen Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Morepen Laboratories Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Morepen Laboratories Ltd said on order book & pipeline — free account, 30 seconds.

Morepen Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Morepen Laboratories Ltd Q2 FY26 results — key figures

Morepen Laboratories Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue412438-5.9%425-3.1%
Operating profit (EBITDA)3144-29.5%24+29.2%
Operating margin7%10%-3 pp6%+1 pp
Profit before tax46460%16+187.5%
Net profit (PAT)4135+17.1%11+272.7%
EPS (₹)0.750.64+17.2%0.20+275%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Morepen Laboratories Ltd Q2 FY26 results?

Pharma Business (Total Revenue): EBITDA:

What is Morepen Laboratories Ltd share price analysis?

Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.